delavirdine has been researched along with HIV Coinfection in 95 studies
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C(min)), and virologic response." | 2.71 | Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. ( Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D, 2004) |
| "Delavirdine is a non-nucleoside reverse transcriptase inhibitor used in combination regimens for the treatment of HIV-1 infection." | 2.71 | Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ( Dicenzo, R; DiFrancesco, R; Fischl, M; Forrest, A; Friedland, G; Morse, GD; Para, M; Pollard, R; Shelton, M; Smith, PF, 2005) |
| " Skin rash was the most frequently observed adverse event (52%)." | 2.69 | Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. ( Been-Tiktak, AM; Borleffs, JC; Boucher, CA; Brun-Vezinet, F; Colebunders, R; Cooper, DA; Gatell, JM; Hawkins, DA; Hoy, JF; Johnson, MA; Joly, V; Jost, J; Kennedy, DH; Moroni, M; Mulder, JW; Parkin, JM; Staszewski, S; Stewart, GJ, 1999) |
| " In this study, therapy with delavirdine + zidovudine + didanosine was safe and showed modest, but not always significant, antiviral activity and CD4 cell count benefit compared with two-drug regimens with these agents." | 2.69 | Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. ( Bassett, R; Connick, E; Demeter, L; Fischl, M; Freimuth, W; Friedland, GH; Griffith, B; Hirsch, M; Hughes, M; Morse, G; Nevin, T; Pollard, R, 1999) |
| " These drug-drug interactions were not expected, the mechanism(s) is (are) not clear, and additional studies are warranted." | 2.69 | Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. ( Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP, 2000) |
| " DLV demonstrated good oral bioavailability at all five doses tested." | 2.68 | Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. ( Boyle, J; Chaitt, DG; Coleman, S; Cox, SR; Daenzer, CL; Davey, RT; Eastman, PS; Falloon, J; Freimuth, WW; Herpin, BR; Kovacs, JA; Lane, HC; Masur, H; Metcalf, JA; Polis, MA; Reed, GF; Walker, RE; Wathen, L, 1996) |
| " On day 30, statistically significant differences between groups were observed for all delavirdine pharmacokinetic parameters (P < 0." | 2.68 | Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. ( Aksentijevich, S; Borin, MT; Carel, BJ; Chambers, JH; Freimuth, WW; Piergies, AA, 1997) |
| " PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects." | 2.42 | Clinical utility of current NNRTIs and perspectives of new agents in this class under development. ( Hamatake, R; Hong, Z; Zhang, Z, 2004) |
| "Delavirdine is an effective component of recommended antiretroviral treatment strategies for adult patients with HIV infection and, in combination with 2 NRTIs as a first-line therapy, the drug has the advantage of sparing protease inhibitors for subsequent use." | 2.41 | Delavirdine: a review of its use in HIV infection. ( Perry, CM; Scott, LJ, 2000) |
| " The ability of delavirdine to enhance the pharmacokinetic profiles of protease inhibitors may permit the use of simplified administration regimens." | 2.41 | Delavirdine: clinical pharmacokinetics and drug interactions. ( Gerber, JG; Kerr, BM; Tran, JQ, 2001) |
| " Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics." | 2.41 | Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. ( DiCenzo, R; Morse, GD; Smith, PF, 2001) |
| "To evaluate the pharmacokinetic effect of adding delavirdine mesylate to the antiretroviral regimens of human immunodeficiency virus (HIV)-infected patients stabilized on a full dosage of ritonavir (600 mg every 12 h), 12 HIV-1-infected subjects had delavirdine mesylate (400 mg every 8 h) added to their current antiretroviral regimens for 21 days." | 1.32 | Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ( Adams, J; Cox, S; Della-Coletta, A; Hewitt, RG; Morse, GD; Shelton, MJ, 2003) |
| "When delavirdine was combined with a PI, there was a more dramatic increase in both cholesterol and HDL concentrations." | 1.31 | Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. ( Chinn, C; Hsia, J; Liappis, AP; Muesing, RA; Parenti, DM; Roberts, AD; Schuck, SZ; Simon, GL, 2002) |
| "Delavirdine is a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1-infected patients." | 1.30 | Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. ( Beijnen, JH; Hoetelmans, RM; Lange, JM; Meenhorst, PL; Mulder, JW; van Heeswijk, RP; Veldkamp, AI, 1999) |
| " The bioavailability of soft-gel saquinavir (Fortovase) compared with the hard gel formulation (Invirase) is discussed." | 1.30 | Product information. ( Bartlett, JG, 1998) |
| " Two other studies examined different dosages of Nelfinavir or Indinavir and found that twice-a-day dosing may be as effective as three times a day." | 1.30 | Antiviral update. ( , 1998) |
| "Nevirapine was shown to be most effective in trials with triple combination regimens." | 1.30 | NNRTIs: a neglected class. ( Cadman, J, 1998) |
| " Several studies of regimens that include protease inhibitors compare dosing twice daily to three times a day." | 1.30 | Antivirals update. ( , 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 38 (40.00) | 18.2507 |
| 2000's | 42 (44.21) | 29.6817 |
| 2010's | 14 (14.74) | 24.3611 |
| 2020's | 1 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Zhan, P | 7 |
| Liu, X | 7 |
| Cao, Y | 1 |
| Wang, Y | 1 |
| Pannecouque, C | 7 |
| De Clercq, E | 7 |
| Fletcher, P | 1 |
| Harman, S | 1 |
| Azijn, H | 1 |
| Armanasco, N | 1 |
| Manlow, P | 1 |
| Perumal, D | 1 |
| de Bethune, MP | 1 |
| Nuttall, J | 1 |
| Romano, J | 1 |
| Shattock, R | 1 |
| Varghese, V | 1 |
| Mitsuya, Y | 1 |
| Shahriar, R | 1 |
| Bachmann, MH | 1 |
| Fessel, WJ | 1 |
| Kagan, RM | 1 |
| Shafer, RW | 2 |
| Fang, Z | 1 |
| Li, Z | 2 |
| Gupta, S | 1 |
| Fransen, S | 1 |
| Paxinos, EE | 1 |
| Stawiski, E | 1 |
| Huang, W | 1 |
| Petropoulos, CJ | 1 |
| Zeng, ZS | 1 |
| He, QQ | 1 |
| Liang, YH | 1 |
| Feng, XQ | 1 |
| Chen, FE | 1 |
| Balzarini, J | 2 |
| Chen, W | 2 |
| Li, X | 2 |
| Chen, X | 1 |
| Tian, Y | 2 |
| Clercq, ED | 1 |
| Li, D | 1 |
| Liu, H | 1 |
| Yang, J | 1 |
| Kang, D | 2 |
| Lu, X | 1 |
| Liu, Z | 2 |
| Huang, B | 2 |
| Daelemans, D | 2 |
| Gu, SX | 1 |
| Xue, P | 1 |
| Ju, XL | 1 |
| Zhu, YY | 1 |
| Liu, J | 1 |
| Zhang, H | 1 |
| Lee, KH | 1 |
| Chen, CH | 1 |
| Namasivayam, V | 1 |
| Vanangamudi, M | 1 |
| Kramer, VG | 1 |
| Kurup, S | 1 |
| Kongsted, J | 1 |
| Byrareddy, SN | 1 |
| Singh, VK | 1 |
| Mishra, R | 1 |
| Kumari, P | 1 |
| Som, A | 1 |
| Yadav, AK | 1 |
| Ram, NK | 1 |
| Kumar, P | 1 |
| Schols, D | 1 |
| Singh, RK | 1 |
| Sterrantino, G | 1 |
| Borghi, V | 1 |
| Callegaro, AP | 1 |
| Bruzzone, B | 1 |
| Saladini, F | 1 |
| Maggiolo, F | 1 |
| Maffongelli, G | 1 |
| Andreoni, M | 1 |
| De Gennaro, M | 1 |
| Gianotti, N | 2 |
| Bagnarelli, P | 1 |
| Vergori, A | 1 |
| Antinori, A | 1 |
| Zazzi, M | 1 |
| Zaccarelli, M | 1 |
| Iqbal, HS | 1 |
| Solomon, SS | 1 |
| Saravanan, S | 1 |
| Vidya, M | 1 |
| Kumarasamy, N | 1 |
| Solomon, S | 1 |
| Balakrishnan, P | 1 |
| Costa, S | 1 |
| Machado, M | 1 |
| Cavadas, C | 1 |
| do Céu Sousa, M | 1 |
| Xu, H | 1 |
| Schrijvers, R | 1 |
| Desimmie, BA | 1 |
| Debyser, Z | 1 |
| Kuo, YC | 1 |
| Lee, CL | 1 |
| Gulick, RM | 4 |
| Hu, XJ | 3 |
| Fiscus, SA | 2 |
| Fletcher, CV | 4 |
| Haubrich, R | 4 |
| Cheng, H | 3 |
| Acosta, E | 2 |
| Lagakos, SW | 2 |
| Swanstrom, R | 2 |
| Freimuth, W | 4 |
| Snyder, S | 2 |
| Mills, C | 3 |
| Fischl, M | 5 |
| Pettinelli, C | 2 |
| Katzenstein, D | 4 |
| Roberts, AD | 1 |
| Liappis, AP | 1 |
| Chinn, C | 1 |
| Parenti, DM | 1 |
| Muesing, RA | 1 |
| Schuck, SZ | 1 |
| Hsia, J | 1 |
| Simon, GL | 1 |
| Shelton, MJ | 2 |
| Hewitt, RG | 2 |
| Adams, JM | 1 |
| Cox, SR | 2 |
| Chambers, JH | 2 |
| Morse, GD | 5 |
| Adams, J | 1 |
| Della-Coletta, A | 1 |
| Cox, S | 2 |
| Moreno, S | 1 |
| Casado, JL | 2 |
| Pérez-Elías, MJ | 1 |
| Dronda, F | 2 |
| Antela, A | 1 |
| Moreno, A | 1 |
| Gutiérrez, C | 1 |
| Kontorinis, N | 1 |
| Dieterich, DT | 1 |
| Moyle, GJ | 1 |
| Wood, E | 1 |
| Hogg, RS | 1 |
| Heath, KV | 1 |
| de la Rosa, R | 1 |
| Lee, N | 1 |
| Yip, B | 1 |
| O'Shaughnessy, MV | 1 |
| Montaner, JS | 2 |
| Jiang, H | 1 |
| Brundage, RC | 1 |
| Acosta, EP | 2 |
| Engelhorn, C | 2 |
| Hoffmann, F | 2 |
| Kurowski, M | 2 |
| Stocker, H | 1 |
| Kruse, G | 1 |
| Notheis, G | 2 |
| Belohradsky, BH | 2 |
| Wintergerst, U | 2 |
| Zhang, Z | 1 |
| Hamatake, R | 1 |
| Hong, Z | 1 |
| Smith, PF | 2 |
| Dicenzo, R | 2 |
| Forrest, A | 1 |
| Shelton, M | 1 |
| Friedland, G | 2 |
| Para, M | 1 |
| Pollard, R | 2 |
| DiFrancesco, R | 1 |
| Boeri, E | 1 |
| Maillard, M | 1 |
| Serra, G | 1 |
| Ratti, D | 1 |
| Gallotta, G | 1 |
| Vacchini, D | 1 |
| Tremolada, Y | 1 |
| Castagna, A | 1 |
| McCance-Katz, EF | 1 |
| Moody, DE | 1 |
| Pade, P | 1 |
| Baker, J | 1 |
| Alvanzo, A | 1 |
| Smith, P | 1 |
| Ogundele, A | 1 |
| Jatlow, P | 1 |
| Rainey, PM | 1 |
| Huang, IC | 2 |
| Willke, RJ | 3 |
| Atkinson, MJ | 2 |
| Lenderking, WR | 1 |
| Frangakis, C | 2 |
| Wu, AW | 2 |
| Kurle, SN | 1 |
| Gangakhedkar, RR | 1 |
| Sen, S | 1 |
| Hayatnagarkar, SS | 1 |
| Tripathy, SP | 1 |
| Paranjape, RS | 1 |
| Leite, WL | 1 |
| Vogel, WB | 1 |
| Dueweke, TJ | 1 |
| Poppe, SM | 1 |
| Romero, DL | 1 |
| Swaney, SM | 1 |
| So, AG | 1 |
| Downey, KM | 1 |
| Althaus, IW | 1 |
| Reusser, F | 1 |
| Busso, M | 1 |
| Resnick, L | 1 |
| Davey, RT | 1 |
| Chaitt, DG | 1 |
| Reed, GF | 1 |
| Freimuth, WW | 5 |
| Herpin, BR | 1 |
| Metcalf, JA | 1 |
| Eastman, PS | 1 |
| Falloon, J | 1 |
| Kovacs, JA | 1 |
| Polis, MA | 1 |
| Walker, RE | 1 |
| Masur, H | 1 |
| Boyle, J | 1 |
| Coleman, S | 1 |
| Wathen, L | 1 |
| Daenzer, CL | 1 |
| Lane, HC | 1 |
| Demeter, LM | 3 |
| Meehan, PM | 2 |
| Morse, G | 2 |
| Gerondelis, P | 1 |
| Dexter, A | 1 |
| Berrios, L | 1 |
| Reichman, RC | 2 |
| Borin, MT | 1 |
| Carel, BJ | 1 |
| Aksentijevich, S | 1 |
| Piergies, AA | 1 |
| Miller, V | 1 |
| Staszewski, S | 2 |
| Boucher, CA | 2 |
| Phair, JP | 1 |
| Holtzer, CD | 1 |
| Coleman, RL | 1 |
| Bellman, PC | 1 |
| Saag, MS | 1 |
| Schooley, RT | 1 |
| Been-Tiktak, AM | 1 |
| Brun-Vezinet, F | 1 |
| Joly, V | 2 |
| Mulder, JW | 2 |
| Jost, J | 2 |
| Cooper, DA | 1 |
| Moroni, M | 2 |
| Gatell, JM | 1 |
| Colebunders, R | 1 |
| Stewart, GJ | 1 |
| Hawkins, DA | 2 |
| Johnson, MA | 1 |
| Parkin, JM | 1 |
| Kennedy, DH | 1 |
| Hoy, JF | 1 |
| Borleffs, JC | 1 |
| Veldkamp, AI | 1 |
| van Heeswijk, RP | 1 |
| Hoetelmans, RM | 1 |
| Meenhorst, PL | 1 |
| Lange, JM | 1 |
| Beijnen, JH | 1 |
| Friedland, GH | 1 |
| Griffith, B | 1 |
| Hughes, M | 1 |
| Bassett, R | 1 |
| Demeter, L | 1 |
| Connick, E | 1 |
| Nevin, T | 1 |
| Hirsch, M | 1 |
| Crowe, S | 1 |
| Temesgen, Z | 1 |
| Wright, AJ | 1 |
| Clotet, B | 2 |
| Holden-Wiltse, J | 1 |
| Fischl, MA | 1 |
| Para, MF | 1 |
| Hertogs, K | 2 |
| Ruiz, L | 1 |
| Van Cauwenberge, A | 1 |
| Arnó, A | 1 |
| Garcia-Arata, I | 1 |
| Bloor, S | 1 |
| Bonjoch, A | 1 |
| Blazquez, J | 1 |
| Larder, B | 2 |
| Weinfurt, KP | 1 |
| Glick, HA | 1 |
| Schulman, KA | 1 |
| Conway, B | 1 |
| Concia, E | 1 |
| Lazzarin, A | 1 |
| Hirschel, B | 1 |
| Chiodo, F | 1 |
| Bentwich, Z | 1 |
| Love, WC | 1 |
| Wilkins, EG | 1 |
| Gatell, AJ | 1 |
| Vetter, N | 1 |
| Greenwald, C | 1 |
| de Cian, W | 1 |
| Raasch, R | 1 |
| Remmel, RP | 1 |
| Scott, LJ | 1 |
| Perry, CM | 1 |
| Deeks, SG | 1 |
| Tran, JQ | 1 |
| Gerber, JG | 1 |
| Kerr, BM | 1 |
| Bacheler, L | 1 |
| Jeffrey, S | 1 |
| Hanna, G | 1 |
| D'Aquila, R | 1 |
| Wallace, L | 1 |
| Logue, K | 1 |
| Cordova, B | 1 |
| Buckery, R | 1 |
| Baker, D | 1 |
| Gallagher, K | 1 |
| Scarnati, H | 1 |
| Tritch, R | 1 |
| Rizzo, C | 1 |
| James, JS | 2 |
| Bowers, M | 1 |
| Smart, T | 2 |
| Torres, G | 1 |
| Gilden, D | 1 |
| Mascolini, M | 2 |
| Bartlett, JG | 2 |
| Cadman, J | 1 |
| Dykes, C | 1 |
| Fox, K | 1 |
| Lloyd, A | 1 |
| Chiulli, M | 1 |
| Morse, E | 1 |
| Castro, JG | 1 |
| Gutierrez, L | 1 |
| Harris, M | 1 |
| Alexander, C | 1 |
| O'Shaughnessy, M | 1 |
| Rezk, NL | 1 |
| Tidwell, RR | 1 |
| Kashuba, AD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copie[NCT00000892] | 300 participants | Interventional | Completed | ||||
| CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics[NCT00666055] | 11 participants (Actual) | Observational | 2008-03-31 | Completed | |||
| A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy[NCT00000803] | Phase 2 | 471 participants | Interventional | Completed | |||
| Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)[NCT00000810] | Phase 1 | 120 participants | Interventional | Completed | |||
| A Prospective, Randomized, Comparative Study of the Safety and Efficacy of Clarithromycin Versus Rifabutin Versus the Combination of Clarithromycin Plus Rifabutin for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disea[NCT00001030] | Phase 3 | 1,100 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for delavirdine and HIV Coinfection
| Article | Year |
|---|---|
Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
Topics: Anti-HIV Agents; Drug Design; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcripta | 2016 |
Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Topics: Anti-HIV Agents; Delavirdine; Drug Design; Drug Synergism; Drug Therapy, Combination; HIV Infections | 2010 |
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind | 2003 |
Protease inhibitor-sparing regimens: new evidence strengthens position.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as | 2003 |
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis | 2004 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N | 1997 |
Use of nonnucleoside reverse-transcriptase inhibitors.
Topics: Anti-HIV Agents; Delavirdine; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcr | 1998 |
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV I | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; | 1998 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; D | 1999 |
Efavirenz: resistance and cross-resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Geno | 1999 |
Delavirdine: a review of its use in HIV infection.
Topics: Anti-HIV Agents; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibi | 2000 |
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug R | 2001 |
Delavirdine: clinical pharmacokinetics and drug interactions.
Topics: Delavirdine; Drug Interactions; HIV Infections; HIV Reverse Transcriptase; Humans; Intestinal Absorp | 2001 |
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Femal | 2001 |
15 trials available for delavirdine and HIV Coinfection
| Article | Year |
|---|---|
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therapy, Combination; | 2002 |
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity.
Topics: Adult; Area Under Curve; Beverages; Citrus; Cross-Over Studies; Delavirdine; Female; Gastric Mucosa; | 2003 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Topics: Adolescent; Adult; Anti-HIV Agents; Body Weight; Carbamazepine; Delavirdine; Double-Blind Method; Dr | 2005 |
US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug The | 2007 |
Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease.
Topics: Anti-HIV Agents; Data Interpretation, Statistical; Delavirdine; HIV Infections; HIV-1; Humans; Model | 2008 |
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Topics: Adult; Anti-HIV Agents; Biological Availability; Delavirdine; Didanosine; Dose-Response Relationship | 1996 |
Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A | 1997 |
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Drug Therapy, Combination; HIV Infections; Human | 1999 |
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug The | 1999 |
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Topics: Adult; Anti-HIV Agents; Delavirdine; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse | 2000 |
Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Dr | 2000 |
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therap | 2000 |
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combina | 2000 |
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Interactions; Drug Therapy, | 2000 |
64 other studies available for delavirdine and HIV Coinfection
| Article | Year |
|---|---|
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluatio | 2008 |
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infect | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse | 2009 |
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum | 2009 |
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reve | 2010 |
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; | 2010 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Mole | 2012 |
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyrida | 2013 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Human | 2016 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Do | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; R | 2019 |
In silico design, synthesis and anti-HIV activity of quinoline derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Topics: Catalytic Domain; Delavirdine; Drug Design; HIV Infections; HIV Reverse Transcriptase; Humans; Molec | 2022 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; | 2019 |
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype | 2011 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co | 2016 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; | 2011 |
Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.
Topics: Ammonium Sulfate; Anti-HIV Agents; Astrocytes; Biological Transport; Blood-Brain Barrier; Bradykinin | 2012 |
Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy.
Topics: Anti-HIV Agents; Cholesterol; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; | 2002 |
Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2D6; Cy | 2003 |
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis | 2003 |
Pfizer announces free drug program.
Topics: Anti-Retroviral Agents; Delavirdine; Drug Industry; HIV Infections; Humans; Nelfinavir; United State | 2003 |
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2003 |
Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Carbamates; Child; Delavirdine; Drug Combinations; Fu | 2004 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; | 2004 |
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Buprenorphine; Case-Control Studies; Cohort Studies; | 2006 |
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Fema | 2007 |
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
Topics: Antiviral Agents; Cell Line; Delavirdine; Drug Resistance, Microbial; HIV Infections; HIV Reverse Tr | 1993 |
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Topics: Adult; Anti-HIV Agents; Delavirdine; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combinati | 1997 |
FDA approvals include two new AIDS drugs, pediatric labeling for two protease inhibitors.
Topics: Adolescent; Adult; Child; Child, Preschool; Delavirdine; Drug Approval; Drug Labeling; HIV Infection | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Inte | 1997 |
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Drug Therapy, Combination; Female; HIV In | 1998 |
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Delavirdine; Drug Monitoring; HIV Infections; | 1999 |
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial | 2000 |
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Pr | 2000 |
Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Child; Child, Preschool; Cyclopropan | 2000 |
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, P | 2001 |
Delaviridine and AZT combination tested in women.
Topics: Anti-HIV Agents; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; Humans; Reverse Tra | 1997 |
Viral load: new confirmation from major delavirdine studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; HIV; HIV Infections; | 1996 |
Delavirdine available on expanded access.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; HIV Infections; Humans; Indoles; Pipera | 1996 |
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; | 1996 |
Delavirdine expanded access program.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Delavirdine; Female; HIV Infections; Humans; Indoles; Male; | 1996 |
Nevirapine and delavirdine plus protease inhibitors.
Topics: Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Ne | 1996 |
Antiviral roundup.
Topics: CD4 Lymphocyte Count; Cohort Studies; Delavirdine; Didanosine; Drug Therapy, Combination; HIV Infect | 1996 |
A new class of anti-HIV drugs.
Topics: Delavirdine; HIV Infections; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors | 1996 |
Delavirdine/protease inhibitor interactions.
Topics: Delavirdine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; | 1996 |
Delavirdine dilemma at the FDA. Food and Drug Administration.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Delavirdine; Drug Approval; Drug Interactions; Drug Thera | 1996 |
FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Didanosine; Disease P | 1996 |
Delavirdine data: skewed or skewered?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Data Interpretation, Statistical; D | 1997 |
Delavirdine (Rescriptor) approved.
Topics: Anti-HIV Agents; Delavirdine; Didanosine; Drug Approval; Drug Costs; Drug Therapy, Combination; HIV | 1997 |
Delavirdine gains approval as second NNRTI for anti-HIV combination regimens.
Topics: Delavirdine; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; Humans; Indoles; Male | 1997 |
New developments in women and AIDS research.
Topics: AIDS-Related Opportunistic Infections; Delavirdine; Drug Therapy, Combination; Estrogens; Female; HI | 1997 |
Product information.
Topics: Anti-Infective Agents; Bacterial Infections; Biological Availability; Capsules; Clinical Trials as T | 1998 |
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
Topics: Adolescent; Adult; Anti-HIV Agents; Delavirdine; HIV Infections; Humans; Nevirapine; Reverse Transcr | 1998 |
Antiviral update.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Drug Therapy, Combinat | 1998 |
NNRTIs: a neglected class.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microb | 1998 |
Strategy update: protease-sparing regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Pr | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Thera | 1998 |
Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Topics: Anti-HIV Agents; Cell Line; Delavirdine; Drug Resistance, Microbial; HIV Infections; HIV Reverse Tra | 2001 |
Delavirdine (Rescriptor).
Topics: Delavirdine; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Practice Guidelines as Topic; | 2000 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV | 2001 |
FDA approves new versions of two HIV/AIDS drugs.
Topics: Delavirdine; Drug Administration Schedule; Drug Approval; HIV Infections; Humans; Nelfinavir; Revers | 2000 |
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
Topics: Acute Kidney Injury; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A | 2002 |
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Delavirdine; Drug Synergism; Fur | 2002 |
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infecti | 2002 |